Bionano Genomics, Inc. (BNGO)

Market Cap	11.44M
Revenue (ttm)	28.46M
Net Income (ttm)	-83.70M
Shares Out	3.36M
EPS (ttm)	-48.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,545
Open	3.400
Previous Close	3.400
Day's Range	3.357 - 3.420
52-Week Range	2.680 - 41.334
Beta	2.21
Analysts	Buy
Price Target	7.33 (+115.59%)
Earnings Date	Aug 6, 2025

About BNGO

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. The company offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA lin...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 21, 2018
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: BNGO
• Website: https://www.bionano.com

Financial Performance

In 2024, Bionano Genomics's revenue was $30.78 million, a decrease of -14.79% compared to the previous year's $36.12 million. Losses were -$112.02 million, -51.82% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for BNGO stock is "Buy." The 12-month stock price target is $7.33, which is an increase of 115.59% from the latest price.

Price Target

$7.33

(115.59% upside)

Analyst Consensus: Buy